Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.

The British journal of ophthalmology - 1 Dec 2015

Riechardt Aline I, Maier Anna-Karina B, Nonnenmacher Anika, Reichhart Nadine, Keilholz Ulrich, Kociok Norbert, Strauss Olaf, Joussen Antonia M, Gundlach Enken

Abstract excerpt

PURPOSE: Mutations in the gene coding for the kinase B-Raf are associated with tumour growth in conjunctival melanoma. The purpose of this study is to explore effects of pharmacological B-Raf inhibition in conjunctival melanoma cell lines. METHODS: The B-Raf genotypes were assessed by PCR and subsequent sequencing. Cytotoxicity, cell viability, proliferation, apoptosis rate and phosphorylation rate of ERK and Akt...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Conjunctival Neoplasms
Share to Enzyme-Linked Immunosorbent Assay

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunoblotting

Share to Indoles

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Identifiers

PMID: 26347528
DOI: 10.1136/bjophthalmol-2015-306689

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.PMID 26347528Read ↗

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant MelanomaSemantic proximity Read ↗

Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.Semantic proximity Read ↗

A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.Semantic proximity Read ↗

Specifically targeting ERK1 or ERK2 kills Melanoma cellsSemantic proximity Read ↗

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.Semantic proximity Read ↗

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.Semantic proximity Read ↗

Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.Semantic proximity Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib.Semantic proximity Read ↗

Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.Semantic proximity Read ↗

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.Semantic proximity Read ↗

Investigating Therapeutic Efficacy of Dacarbazine and Temozolomide, Alone and in Combination with BRAF(V600E) siRNA in A375 Human Melanoma Cell LineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.